The shift towards antibiotic-free acne treatments
Why Benzalkonium Chloride (BKC)?
Application study: BKC in semi-solid formulations
Recent application research from Novo Nordisk Pharmatech explores the potential of low concentrations of BKC in semisolid acne formulations.
In the study, hydroxyethyl cellulose (HEC) gel formulations containing 0.03%, 0.06% and 0.13% BKC were evaluated against several acne-related microorganisms, including:
- Cutibacterium acnes
- Staphylococcus aureus
- MRSA
- Staphylococcus epidermidis
Results demonstrated rapid antimicrobial efficacy, achieving reductions of ≥4.5–5 log₁₀ within two hours — even at the lowest BKC concentration.
Stability and formulation reliability
To support formulation reliability, BKC content and stability were confirmed using a modified USP HPLC method, ensuring consistent potency over time.
Skin compatibility for daily use
Dermal tolerability was also evaluated using an ISO-standard irritation study. Low BKC concentrations demonstrated good skin compatibility comparable to a benzoyl peroxide control, highlighting the suitability of BKC for daily topical use.
Supporting next-generation acne formulations
These results demonstrate how Benzalkonium Chloride may support the development of antibiotic-free acne treatments with strong antimicrobial performance and favorable skin tolerability.
For more detailed results and formulation insights, download the full application note from Novo Nordisk Pharmatech.

